Albireo Pharma Inc Stock News

– Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters –

– Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay™ (odevixibat) –

– Data being presented show long-term benefits of Bylvay in children with PFIC –

Mirum Is Undervalued Despite Expected Tough Competition

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief

European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for

– Bylvay has the potential to become first approved drug to treat all forms of PFIC –

- PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC -

Mirum: Rare Disease Play With Upcoming Catalysts

Albireo Pharma (ALBO) CEO Ron Cooper on Q1 2021 Results - Earnings Call Transcript

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement

– Bylvay TM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU–

Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat

– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs –

BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the